Degree of bioresorbable vascular scaffold expansion modulates loss of essential function.
Drug-eluting bioresorbable vascular scaffolds (BVSs) have the potential to restore lumen patency, enable recovery of the native vascular environment, and circumvent late complications associated with permanent endovascular devices. To ensure therapeutic effects persist for sufficient times prior to scaffold resorption and resultant functional loss, many factors dictating BVS performance must be identified, characterized and optimized. While some factors relate to BVS design and manufacturing, others depend on device deployment and intrinsic vascular properties. Importantly, these factors interact and cannot be considered in isolation. The objective of this study is to quantify the extent to which degree of radial expansion modulates BVS performance, specifically in the context of modifying device erosion kinetics and evolution of structural mechanics and local drug elution. We systematically varied degree of radial expansion in model BVS constructs composed of poly dl-lactide-glycolide and generated in vitro metrics of device microstructure, degradation, erosion, mechanics and drug release. Experimental data permitted development of computational models that predicted transient concentrations of scaffold-derived soluble species and drug in the arterial wall, thus enabling speculation on the short- and long-term effects of differential expansion. We demonstrate that degree of expansion significantly affects scaffold properties critical to functionality, underscoring its relevance in BVS design and optimization.


CONCLUSIONS
Bioresorbable vascular scaffold (BVS) therapy is beginning to transform the treatment of obstructive artery disease, owing to effective treatment of short term vessel closure while avoiding long term consequences such as in situ, late stent thrombosis - a fatal event associated with permanent implants such as drug-eluting stents. As device scaffolding and drug elution are temporary for BVS, the notion of using this therapy in lieu of existing, clinically approved devices seems attractive. However, there is still a limited understanding regarding the optimal lifetime and performance characteristics of erodible endovascular implants. Several engineering criteria must be met and clinical endpoints confirmed to ensure these devices are both safe and effective. In this manuscript, we sought to establish general principles for the design and deployment of erodible, drug-eluting endovascular scaffolds, with focus on how differential expansion can modulate device performance.
Biomedical Engineering Program, College of Engineering and Computing, University of South Carolina, Columbia, SC 29208, USA.
Jahid
J
Ferdous
Charles Stark Draper Laboratory, Cambridge, MA 02139, USA; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Vijaya B
VB
Kolachalama
Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Kumaran
K
Kolandaivelu
Biomedical Engineering Program, College of Engineering and Computing, University of South Carolina, Columbia, SC 29208, USA; Department of Mechanical Engineering, College of Engineering and Computing, University of South Carolina, Columbia, SC 29208, USA. Electronic address: shazly@cec.sc.edu.
Tarek
T
Shazly
D020341:Absorbable Implants; D001807:Blood Vessel Prosthesis; D001826:Body Fluids / Q000737:chemistry; D017076:Computer-Aided Design; D003343:Corrosion; D004058:Diffusion; D004343:Drug Implants / Q000008:administration & dosage / Q000737:chemistry*; D054855:Drug-Eluting Stents; D004867:Equipment Design; D019544:Equipment Failure Analysis; D019344:Lactic Acid / Q000737:chemistry; D017239:Paclitaxel / Q000008:administration & dosage / Q000737:chemistry*; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D054457:Tissue Scaffolds; D058017:Vascular Grafting / Q000295:instrumentation
D004343:Drug Implants; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D017239:Paclitaxel
Bioresorbable vascular scaffolds; Computational modeling; Drug delivery; Radial expansion